An injection given four times a year cut acute pancreatitis events by 78 percent in adults with severely elevated triglycerides, according to results presented August 30, 2026, at the European Society of Cardiology Congress in Munich. In the subgroup at highest risk, patients with triglycerides above 880 milligrams per deciliter and a prior pancreatitis attack, no events were recorded among those treated.
The drug is plozasiran, an RNA interference therapy that reduces liver production of apolipoprotein C-III, a protein that governs how the body clears triglycerides from the blood. It is already approved for a rare inherited disorder under the brand name Redemplo, for familial chylomicronemia syndrome, the rarest and most extreme form of the condition. These trials tested it in the far larger group of adults with severe hypertriglyceridemia.
